Anti-CD3 mAbs for treatment of type 1 diabetes (Q28239248)

Diabetes - Metabolism: Research and Reviews

Europe PubMed Central

title

Anti-CD3 mAbs for treatment of type 1 diabetes (English)

0 references

0 references

Adam Kaufman

1

0 references

Kevan C Herold

series ordinal

2

0 references

language of work or name

English

0 references

publication date

May 2009

0 references

published in

0 references

volume

25

0 references

issue

4

0 references

page(s)

302-6

0 references

cites work

Ten years of Orthoclone OKT3 (muromonab-CD3): a review

1 reference

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

21 January 2018

1 reference

ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease?

21 January 2018

1 reference

7 January 2021

Factors associated with early remission of type I diabetes in children treated with cyclosporine

1 reference

7 January 2021

Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus

1 reference

7 January 2021

Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?

1 reference

7 January 2021

Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients

1 reference

7 January 2021

Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection

1 reference

7 January 2021

Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb

1 reference

7 January 2021

Treatment of acute renal allograft rejection with OKT3 monoclonal antibody

1 reference

7 January 2021

Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts

1 reference

7 January 2021

OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival

1 reference

7 January 2021

No long-term benefit of low-dose OKT3 induction therapy in non to moderately immunized renal allograft recipients

1 reference

7 January 2021

OKT3 treatment in refractory pediatric heart transplant rejection

1 reference

7 January 2021

Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation

1 reference

7 January 2021

OKT3 rescue for steroid-resistant rejection in adult liver transplantation.

1 reference

7 January 2021

Use of OKT3 for acute myocarditis in infants and children

1 reference

7 January 2021

HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro

1 reference

7 January 2021

PHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION1

1 reference

7 January 2021

In vitro characterization of five humanized OKT3 effector function variant antibodies.

1 reference

7 January 2021

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

1 reference

7 January 2021

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs

1 reference

7 January 2021

HuM291(Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor

1 reference

7 January 2021

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

1 reference

7 January 2021

Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection

1 reference

7 January 2021

Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody

1 reference

7 January 2021

Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody

1 reference

7 January 2021

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

1 reference

7 January 2021

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

1 reference

7 January 2021

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

1 reference

7 January 2021

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

1 reference

7 January 2021

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

1 reference

7 January 2021

Induction of active tolerance and involvement of CD1d-restricted natural killer T cells in anti-CD3 F(ab')2 treatment-reversed new-onset diabetes in nonobese diabetic mice

1 reference

7 January 2021

Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes

1 reference

7 January 2021

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells

1 reference

7 January 2021

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs

1 reference

7 January 2021

Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice

1 reference

7 January 2021

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

1 reference

7 January 2021

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes

1 reference

7 January 2021